NYSE:ZTSPharmaceuticals
Will Librela Safety Scrutiny and Guidance Cut Change Zoetis' (ZTS) Long-Term Narrative?
In recent weeks, Zoetis Inc. has faced renewed scrutiny over its osteoarthritis drug Librela, with management cutting full-year guidance and committing to provide science-based evidence addressing safety concerns raised through social media and lawsuits.
At a series of March healthcare conferences featuring CEO Kristin C. Peck and CFO Wetteny N. Joseph, the company has used its high-profile platform to directly address questions about Librela’s risk–benefit profile and the resilience of its...